A Phase 1 interventional study of Doxorubicin and Trabectedin in Soft Tissue Sarcoma, Sarcoma and Neoplasms, Connective and Soft Tissue, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-10.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing doxorubicin in Sarcoma — 13 open to participants now, 14 under way, 2 of them phase 3. Doxorubicin · Sarcoma.
Among the 65 studies testing doxorubicin in Sarcoma, this one is the 31st largest by enrollment of the 60 interventional ones that give a count, is the only one that started in 2005, is one of 15 in phase 1, and was the 21st registered.
1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →13 of the 65 studies testing doxorubicin in Sarcoma are open now, in 7 countries. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 65–100
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 10+
Fudan University · Sites in China
Ages 18–75
By country, each count listing its studies:
Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 38 · Phase 3 12
First in 1990; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is close to the median of 41 across 1,254 interventional studies indexed under Sarcoma.
Median enrollment 42 across the 60 interventional studies. Of the 43 that completed or were terminated, 13 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
Johnson & Johnson has 5 studies filed under Sarcoma — fewer than ten, so there is no comparison to draw.
2 of the studies testing doxorubicin in Sarcoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03805022Phase 3Institut BergoniéBenefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas | 2026-12 |
| NCT05711615National Cancer Institute (NCI)Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | 2027-05-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 65 studies testing doxorubicin in Sarcoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the dose of the combination of trabectedin (Yondelis) and Doxorubicin for which neutropenia (low white blood cell counts) could be managed with filgrastim (a Granulocyte-Colony Stimulation Factor that is used to help control neutropenia) in patients with a type of cancer called soft tissue sarcoma.
This is a multicenter, open-label (identity of the assigned study treatments will be known to patients and study staff) study to determine the dose of the combination of trabectedin (Yondelis) and Doxorubicin for which the neutropenia (low white blood cell counts) is manageable with the use of filgrastim (an agent used to manage neutropenia) and associated with clinically acceptable number of side effects severe enough to continuation of treatment in patients with recurrent or persistent soft tissue sarcoma (STS, a malignant tumor that attacks the body's infrastructure of fat, muscles, nerves, joints, blood vessels, or deep skin tissues). Patients will be enrolled in the study after all study-specific entry criteria are met and informed consent is obtained. Patients will be required to attend regular clinic visits to receive study medication and have their status monitored. A detailed explanation can be provided by the study physician (Investigator) conducting this study. Doxorubicin (50 to 75 mg/m2) will be given as a 10-15 minute intravenous (i.v.) infusion on Day 1 via a central venous catheter which is a tube placed into a large vein. Trabectedin (0.9 to 1.3 mg/m2) will be given as a 3 hour i.v. infusion, immediately following the administration of doxorubicin. Dexamethasone 20 mg will be given within 1 hour before the start of each doxorubicin i.v. infusion and filgrastim will be administered according to manufacturer's instructions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Doxorubicin (50 to 75 mg/m2) administered intravenously on Day 1 followed by trabectedin (0.9 to 1.3 mg/m2) administered intravenously on Day 1 every 3 weeks for up to 6 cycles. Dexamethasone 20 mg administered intravenously will be given within 1 hour before the start of doxorubicin. Patients may receive filgrastim for unmanageable neutropenia.
Drug: Doxorubicin · Drug: Trabectedin · Drug: Dexamethasone
Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
Number of patients with adverse events as a measure of safety
Time frame: Up to approximately 19 weeks (six 3-week treatment cycles+30 day safety follow up)
The number of patients with clinically relevant changes in clinically laboratory tests
Time frame: Up to approximately19 weeks (six 3-week treatment cycles+30 day safety follow up)
Number of patients with neutropenia
Time frame: Up to approximately19 weeks (six 3-week treatment cycles+30 day safety follow up)
Plasma concentrations of trabectedin (Yondelis)
Time frame: During the first 3 weeks of treatment
Plasma concentrations of Doxorubicin
Time frame: During the first 3 weeks of treatment
Plasma concentrations of Doxorubicinol
Time frame: During the first 3 weeks of treatment
No study locations are listed for this record.
The record gives a start of Apr 2005 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxorubicin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →